







Vita Life Sciences Limited

ASX Code: VSC

**Preliminary Year End Results
31 December 2009**




Brands

	 Dedicated to your health	 THE SCIENCE OF HEALTHY LIVING	 Enriching Lives . Since 1947	 Vital for life
Australia	Y	Y		
Malaysia			Y	Y
Singapore			Y	
Thailand			Y	Y
China	Y		Y	
Indonesia			Y	
Vietnam			Y	



Sales Trend and Debt Levels



Events	2000	2003	2005	2007	2009
Listed on ASX	30.1	15.5	11.1	11.8	17.0
Pan Recall & Delisted					
Eddie Tie appointed MD					
Relisted on ASX					
Health division profitable					

Debt (\$ 'm)	3.5	18.3	21.4	0.8	1.3

- Recovery has been achieved
- Currently in profitable growth phase



Product Reach

- In Australia –products are sold in over 600 health food stores;
- In Malaysia – products are sold in 3 main channels over-the-counter (>800 stores), no-frills and multi-level marketing (2,000 distributors);
- In Singapore – VH products are sold in over 200 stores
- In China, Thailand and Indonesia – less than 100 stores;
- In Vietnam – sales commencing 3Q-2010;
- In Thailand – MLM sales commencing 3Q-2010.






Group's Business Strategy

- OTC – Australia, Malaysia, Singapore (Established markets)
- OTC – Thailand (2007), China (2008), Vietnam (2010), Indonesia (2011)
- MLM – Malaysia (2007), Singapore & Thailand (2010), Indonesia (2011), Vietnam (2013)
- Profit vs sensible market share
- 50 million population markets


Sales Revenue




- Sales grew by 18.5% in 2009 (2008: 21.3%)
- Established business grew by 17.3% (2008: 20.6%)

Sales Revenue - Segment

2009



2008




- Sales growth y-o-y for Australia, Malaysia and Singapore were 26.5%, 10.9% and 3.3% respectively



Normalised Profit

Income Statement (\$ m)	2009	2008
EBIT	(0.1)	0.5
Add / (less):		
Pan TGA Claim (costs) / receipts	0.6	(1.0)
Normalised EBIT	0.5	(0.5)
Interest expense	(0.2)	(0.2)
Normalised net profit after tax	0.3	(0.8)
Normalised EPS	0.6 cts	(1.4) cts

Normalised EBIT



1. *Excluding proceeds from Pan Liquidator of \$0.70 million, \$0.01 million and \$1.04 million in 2005, 2007 and 2008 respectively*
2. *Excluding profit on disposal of Cyclopharm Limited of \$11.8 million in 2006*
3. *Excluding income from settlement of legal case of \$0.36 million and recovery of previously written off receivables of \$0.16 million in 2007*
4. *Excluding Pan TGA Claim costs of \$0.63 million in 2009*



Financial Summary – Balance Sheet

At 31 December (\$ m)	2009	2008
Current assets	6.6	6.2
Non-current assets	2.2	2.4
Total assets	8.8	8.6
Current liabilities	(4.9)	(4.8)
Non-current liabilities	(0.0)	(0.0)
Total liabilities	(4.9)	(4.8)
Net assets	3.9	3.8



Other

- Group has an equity interest of 6.3% (20.1% profit share) in a property project in Malaysia;
- Project has a positive cash flow;
- No funding required from Group.



Health Division Outlook for 2010

- 2009 sales trends forecast to continue
- Continue to invest 30% – 40% of operating profits in new businesses
- Improved profitability after investment in new businesses

Shareholder Information at 31 Jan. '10

Ordinary shares

Ten largest quoted equity security holders	Number held	Percentage of shares issued
Stinoc Pty Limited	8.04	14.8%
Chemical Trustee Limited	7.56	13.9%
Barleigh Wells Limited	7.37	13.6%
Eddie L S Tie	3.35	6.2%
Normandy Finance & Investments Asia Limited	2.15	2.9%
Vital Bio Tech Holdings Limited	1.59	2.8%
Normandy Nominees Limited	1.50	2.5%
OCI Construction Limited	1.37	2.5%
Abasus Investments Limited	1.36	2.4%
South Seas Holdings Pty Limited	1.28	2.3%
	35.57	63.9%
Total shares on issue	54,285,307	100.0%

Category	No of shareholders	%
1 - 1,000	69	8.5%
1,001 - 5,000	340	41.8%
5,001 - 10,000	161	19.8%
10,001 - 100,000	208	25.6%
100,001 and over	36	4.4%
Total shareholders	814	100.0%



Thank You

24 February 2010